SCHEMBL4605969

SCHEMBL4605969

O=C(O)c1cc(OCc2cccc(C(F)(F)F)c2)ccc1NC(=O)C1CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.57
MRGPRX4 Q96LA9 2/20 0.54
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
S1PR1 P21453 4/20 0.53
S1PR5 Q9H228 4/20 0.53
PDGFRA P16234 2/20 0.53
RXFP1 Q9HBX9 2/20 0.52
FFAR1 O14842 1/20 0.52
FFAR4 Q5NUL3 1/20 0.52
PRKX P51817 1/20 0.52
IKBKE Q14164 1/20 0.52
MAOB P27338 4/20 0.51
PIM1 P11309 1/20 0.51
PRKD3 O94806 1/20 0.51
CDK7 P50613 1/20 0.51
JAK3 P52333 1/20 0.51
TNK2 Q07912 1/20 0.51
F10 P00742 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827185 0.85 KDM4E (0.50) MRGPRX4S1PR1F10POLBKDM4E
SCHEMBL1827641 0.84 KDM4E (0.51) RXFP1F10KDM4EHSD17B10
SCHEMBL1825725 0.83 KDM4E (0.47) MRGPRX4RXFP1F10POLBKDM4E
SCHEMBL1825233 0.83 KDR (0.49) F10KDM4EHSD17B10
SCHEMBL1826827 0.83 KDM4E (0.50) S1PR1S1PR5RXFP1FFAR1PRKX
SCHEMBL1824147 0.83 KDM4E (0.47) MRGPRX4FFAR1F10KDM4EHSD17B10
SCHEMBL1822714 0.82 KDM4E (0.49) MRGPRX4S1PR1S1PR5PDGFRAF10
SCHEMBL1825932 0.82 S1PR1 (0.50) S1PR1KDM4EHSD17B10
SCHEMBL1824122 0.82 KDM4E (0.49) RXFP1F10KDM4EHSD17B10
SCHEMBL1826416 0.82 MRGPRX4 (0.50) MRGPRX4S1PR1F10KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 NR4A2 1796/4885MRGPRX4 420/4885MAPT 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.